LSA
ALNY icon

Leonteq Securities AG’s Alnylam Pharmaceuticals ALNY Stock Holding History

Leonteq Securities AG’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$146K Buy
484
+236
+95% +$71.2K 0.01% 627
2026
Q1 		$82.1K Buy
248
+143
+136% +$48.7K ﹤0.01% 770
2025
Q4 		$41.8K Buy
105
+102
+3,400% +$45.1K ﹤0.01% 984
2025
Q3 		$1.37K Sell
3
-26
-90% -$10.6K ﹤0.01% 1239
2025
Q2 		$9.46K Sell
29
-3
-9% -$830 ﹤0.01% 1072
2025
Q1 		$9.07K Sell
32
-115
-78% -$29.6K ﹤0.01% 1057
2024
Q4 		$34.6K Buy
147
+52
+55% +$13.7K ﹤0.01% 892
2024
Q3 		$26.1K Buy
+95
New +$24.7K ﹤0.01% 876
2024
Q2 		– Sell
-1,850
Closed -$276K – 1198
2024
Q1 		$276K Buy
1,850
+1,408
+319% +$235K 0.02% 431
2023
Q4 		$84.6K Sell
442
-141
-24% -$24K ﹤0.01% 670
2023
Q3 		$103K Sell
583
-128
-18% -$24.4K 0.01% 642
2023
Q2 		$135K Sell
711
-96
-12% -$19K 0.01% 614
2023
Q1 		$162K Buy
807
+194
+32% +$40.8K 0.01% 565
2022
Q4 		$146K Sell
613
-525
-46% -$112K 0.01% 602
2022
Q3 		$228K Sell
1,138
-96
-8% -$18.3K 0.01% 507
2022
Q2 		$180K Sell
1,234
-245
-17% -$34.8K 0.01% 573
2022
Q1 		$242K Buy
1,479
+713
+93% +$109K 0.01% 548
2021
Q4 		$130K Sell
766
-1,012
-57% -$188K ﹤0.01% 719
2021
Q3 		$336K Sell
1,778
-245
-12% -$46K 0.01% 499
2021
Q2 		$343K Sell
2,023
-892
-31% -$131K 0.02% 469
2021
Q1 		$412K Buy
2,915
+1,318
+83% +$198K 0.02% 425
2020
Q4 		$208K Buy
+1,597
New +$213K 0.01% 560

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Leonteq Securities AG's ALNY Position: Q2 2026 in Review

Leonteq Securities AG increased its Alnylam Pharmaceuticals (ALNY) stake by 95% in Q2 2026, buying an estimated $71.2K and bringing the position to 484 shares worth $146K. The position accounts for 0.01% of the portfolio, ranked #627.

Leonteq Securities AG first reported a position in ALNY in Q4 2020 and has held it in 22 quarters since. The position peaked at $412K in Q1 2021. 784 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Leonteq Securities AG held 484 shares of Alnylam Pharmaceuticals worth $146K as of Q2 2026.
  • Leonteq Securities AG bought 236 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $71.2K.
  • Alnylam Pharmaceuticals made up 0.01% of Leonteq Securities AG's portfolio in Q2 2026, its #627 holding.
  • Leonteq Securities AG first reported a position in Alnylam Pharmaceuticals in Q4 2020 and has held it in 22 quarters since.
  • Leonteq Securities AG's Alnylam Pharmaceuticals position peaked at $412K in Q1 2021.
  • 784 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Leonteq Securities AG's 13F filing for Q2 2026, filed 27 Jul 2026.